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Prolonged sleep restriction induces 
changes in pathways involved 
in cholesterol metabolism and 
inflammatory responses
Vilma Aho1,*, Hanna M. Ollila1,2,3,4,*, Erkki Kronholm5, Isabel Bondia-Pons6,7, Pasi Soininen8,9, 
Antti J. Kangas8, Mika Hilvo6, Ilkka Seppälä10, Johannes Kettunen2,8,9, Mervi Oikonen11, 
Emma Raitoharju10, Tuulia Hyötyläinen6,7, Mika Kähönen12, Jorma S.A. Viikari13, 
Mikko Härmä14, Mikael Sallinen14,15, Vesa M. Olkkonen16,17, Harri Alenius18, Matti Jauhiainen2, 
Tiina Paunio2,3, Terho Lehtimäki10, Veikko Salomaa19, Matej Orešič6,7, Olli T. Raitakari11,20, 
Mika Ala-Korpela8,9,21,22 & Tarja Porkka-Heiskanen1
Sleep loss and insufficient sleep are risk factors for cardiometabolic diseases, but data on how 
insufficient sleep contributes to these diseases are scarce. These questions were addressed using two 
approaches: an experimental, partial sleep restriction study (14 cases and 7 control subjects) with 
objective verification of sleep amount, and two independent epidemiological cohorts (altogether 
2739 individuals) with questions of sleep insufficiency. In both approaches, blood transcriptome and 
serum metabolome were analysed. Sleep loss decreased the expression of genes encoding cholesterol 
transporters and increased expression in pathways involved in inflammatory responses in both 
paradigms. Metabolomic analyses revealed lower circulating large HDL in the population cohorts 
among subjects reporting insufficient sleep, while circulating LDL decreased in the experimental sleep 
restriction study. These findings suggest that prolonged sleep deprivation modifies inflammatory and 
cholesterol pathways at the level of gene expression and serum lipoproteins, inducing changes toward 
potentially higher risk for cardiometabolic diseases.
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Short sleep duration, complaints of poor sleep quality and diagnosed sleep problems have in epidemiological 
studies been associated with metabolic disorders, which relate to low-grade chronic inflammation, including 
cardiovascular diseases, metabolic syndrome, obesity, and type 2 diabetes mellitus1–4. However, the functional 
pathways and molecules that mediate these effects are largely unknown.
Several previous studies have shown that experimental restriction of sleep to 4–5 h per night for 1–2 weeks 
activates immune responses5–7, down-regulates gene pathways for macromolecular biosynthesis and metabolic 
processes8, and modifies glucose metabolism by inducing insulin resistance9–11. However, the reported serum 
lipid levels, central factors in the pathogenesis of atherosclerosis, have shown only mild, inconsistent, or no 
effects12–14, leaving open the question what specific metabolic modulations induced by sleep restriction could 
explain the increased association of restricted sleep to atherosclerosis, which is characterised by slow build-up 
of lipid plaques in the walls of the arteries, promoted by inflammatory responses and decrease in macrophage 
reverse cholesterol transport (RCT)15.
The duration of sleep restriction in previous studies has ranged from one to five days, which in the develop-
ment of chronic diseases is a short period. In trying to understand the role of restricted sleep as a predisposing 
factor for such diseases, the key questions are: how do the short-term modifications in metabolism and inflam-
mation develop when the duration of the sleep restriction is prolonged, and are these modifications such that 
could explain the association between restricted sleep and increased risk for e.g. atherosclerosis, as evidenced by 
the epidemiological studies?
The assessment of circulating lipid profiles using nuclear magnetic resonance (NMR) spectroscopy goes 
beyond the typically measured total lipids, like total cholesterol and triglycerides, and allows detailed character-
ization of many lipoprotein features at the subclass level, including the size of the particles, which are important 
in lipid physiology and pathophysiology16,17. Analysis of circulating lipid molecules based on mass spectrometry 
(MS), which gives an extensive profile of individual lipid molecules but does not quantify lipoprotein-related 
measures, has previously been applied in circadian research18–21. Recently one short-term sleep deprivation 
study22 and one partial sleep restriction study23 have applied MS-based lipid analyses in serum, while one study 
used NMR to assess urine metabolites in short-term sleep deprivation24, but NMR-based lipoprotein subclass 
analyses have not been used to analyse the effects of sleep loss. The assessment of the relationship between sleep/
sleep insufficiency and metabolomics profiles in large epidemiological cohorts has not, to our knowledge, been 
reported before.
The short-term effects of insufficient sleep were assessed in a highly controlled experiment where a group of 
volunteers restricted their sleep to 4 hours per night during 5 days (sleep restriction, SR, N = 14 cases and N = 7 con-
trols). The results focusing on the immunological effects at the level of gene expression, cytokines, and CRP have been 
previously published5. The putative longer-term effects were assessed in real-life conditions using two independent 
epidemiological cohorts (DILGOM25, N = 518, and Young Finns Study, YFS26, N = 2221), where the insufficiency 
of sleep was evaluated based on self-reported sleep parameters (subjective sleep insufficiency, SSI). Genome-wide 
transcriptome and NMR-based metabolome were obtained from all three samples, and mass spectrometry-based 
lipidome from the SR study participants (see flow of the analyses depicted in Supplementary Fig. S1).
Results
Subjective sleep insufficiency in epidemiological cohorts. Partial sleep loss was induced experimen-
tally as 4 h sleep/night for 5 nights for 14 healthy young males in the SR study (including also 7 control subjects; 
total N = 21; age (mean ± s.d.) 23.2 ± 2.2 y, Supplementary Table S1)5. To study sleep loss in real life conditions, 
subjective feeling of insufficient sleep was assessed using questionnaire information in two epidemiological sam-
ples. In the DILGOM subsample with information of subjective sleep sufficiency and omics data (N = 472, 46% 
men, age (mean ± s.d.) 51.9 ± 13.8 y, Supplementary Table S1)25, we used the question ”Do you, in your opinion, 
sleep enough?”. The answer options were dichotomised, combining subjects reporting to sleep enough “almost 
always” (N = 168) or “often” (N = 218) to a phenotype of ‘subjective sufficient sleep’ (noSSI, N = 386). Subjects 
reporting to “seldom or almost never” (N = 86) sleep enough were considered as having ‘subjective sleep insuffi-
ciency’ (SSI, N = 86, 18.2%).
In the Cardiovascular Risk in Young Finns Study (“Young Finns Study”, YFS; N = 2221, 55% men, age 
(mean ± s.d.) 37.7 ± 5.0 y, Supplementary Table S1) replication cohort26, sufficiency of sleep was assessed using 
two questions: one addressing self-reported sleep duration (“How many hours do you usually sleep per night?”) 
and another on self-reported sleep need (“How many hours of sleep do you need per day to feel well rested?”). 
Subjective sleep duration was subtracted from subjective sleep need, and individuals sleeping more than an hour 
over their sleep need (N = 37, 1.7%) were excluded from further analyses. Remaining subjects were grouped 
into three groups based on their level of SSI: no (or only mild) SSI (sleep need – sleep duration = − 1… 0… 1 h; 
N = 1825, 82.2%), moderate SSI (1.5–2 h; N = 304, 13.7%), and heavy SSI (> 2 h; N = 55, 2.5%). Despite the dif-
ferences in the questions and age groups, the overall prevalence of SSI (mSSI or hSSI), 16.2%, in the YFS sample 
was quite similar to the 18.2% found in the DILGOM. In accordance with these results, the prevalence of “sleep 
debt”, using closely similar criterion as used in the YFS sample, has been earlier found to be 20% in 1004 French 
young adults27.
Gene expression in lipid pathways. Pathway analysis of differentially expressed genes. Gene expres-
sion profiles were analysed from peripheral blood mononuclear cells (PBMC) in the SR study (N = 9 cases, 
N = 4 controls)5 and whole blood in the DILGOM cohort (N = 472) using microarrays. Lipid-related pathways 
were enriched among transcripts down-regulated after 5 nights of experimental SR5. In the epidemiological 
DILGOM sample, linear regression was used to correlate RNA expression with SSI, adjusting for age and gender. 
Transcripts from 725 genes (2% of the total 35,420 transcripts analysed) had lower expression among subjects 
with SSI (N = 86) compared to subjects with no sleep complaints (N = 386) (pointwise P < 0.05). Enrichment 
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of biological processes among these genes was analysed using DAVID Functional Annotation Clustering28. Five 
Gene Ontology (GO) clusters had enrichment scores > 1.3 (referring to geometrical mean of the P values of the 
pathways < 0.05) in subjects with SSI (Supplementary Table S2).
The GO cluster 5 (“Lipid cluster”, P = 0.045, Supplementary Table S2 and Supplementary Fig. S2) included 
4/5 of the top pathways that were enriched among down-regulated genes in the SR study (permuted P < 0.001) 
reported previously (Table 1)5. The Lipid cluster remained significant (P < 0.05) also after including BMI as a 
covariate in the explanatory model.
The common pathways in the experimental SR study and the DILGOM sample were: Cholesterol transport, 
Sterol transport (both P = 0.048), Cholesterol homeostasis and Sterol homeostasis (both with a borderline sig-
nificance of P = 0.052) (Table 1). The genes contributing to these GO pathways in the DILGOM sample were 
ATP-binding cassette, sub-family G, member 1 (ABCG1), caveolin 1 (CAV1), Niemann-Pick disease, type C1 
(NPC1), and Niemann-Pick disease, type C1, gene-like 1 (NPC1L1), while in the experimental SR study they 
were ABCA1 and NPC1. All genes and pathways of the Lipid cluster are shown in Supplementary Fig. S2.
Gene expression replication. Gene expression was measured in the YFS replication sample (N = 1407) 
from whole blood using Illumina microarrays to evaluate whether the expression of the genes found in the 
down-regulated pathways in DILGOM (ABCG1, CAV1, NPC1, and NPC1L1) was lower in subjects with SSI 
also in this sample. The ABCG1 finding replicated (P < 0.05) in this cohort, supporting the suppressive effect of 
subjective sleep loss on this cholesterol transporter.
Serum lipids and lipoproteins. NMR metabolomics. Next, we examined whether the transcriptional 
changes were reflected in the serum lipid and lipoprotein profiles using NMR-based metabolomics analyses. 
This high-throughput method provides concentration information for over 200 metabolic measures, including 
different sized VLDL, IDL, LDL, and HDL particles, various fatty acids, amino acids, and small molecule energy 
metabolites29.
Concentration of lipoprotein particles and their components. In the SR study (N = 14 cases, 6 controls), the 
number of small, medium, and large LDL particles (P after correction < 0.01) as well as small VLDL particles 
(P < 0.05) was decreased after SR compared to BL, while there were no changes in the number of small and 
medium size HDL particles (Fig. 1A, Supplementary Table S3). Large HDL particles showed a trend of increase 
during SR (P before correction for multiple testing < 0.05, not significant after correction). These changes were 
also reflected by changes in LDL/VLDL structural protein apoB-100. ApoB-100 levels decreased (P < 0.005) 
whereas apoA-I (major structural protein in HDL) levels did not change.
In the DILGOM sample (N = 414), the number of serum large HDL particles was lower among individuals 
with SSI (pointwise P < 0.05). SSI had an independent association to large HDL concentration also after adding 
BMI as a covariate in the model (P < 0.05). There was no significant difference in the levels of any of the LDL or 
VLDL subclasses, although there was a consistent trend for increase in both LDL and VLDL particles of all sizes 
(Fig. 1B, Supplementary Table S3).
The lower number of large HDL particles in subjects with SSI replicated (P < 0.005) in the YFS sample 
(N = 2077) (Fig. 2). In this sample, number of XL HDL was also lower (P < 0.005). No differences were observed 
in small or medium HDLs. For the epidemiological samples, age and gender were adjusted for in the linear regres-
sion model. The decrease in large HDL was independently associated with SSI (P < 0.01) also when probable 
self-reported obstructive sleep apnoea (OSA) was included in the model.
Mass spectrometric measurements. In the SR study (N = 14 cases, N = 7 controls), molecular lipids were further 
analysed with MS-based lipidomics. Altogether 20 lipids were increased after SR in the sleep-deprived cases 
Gene Ontology Pathway Experimental SR Epidemiological SSI
GO ID Name Genes N P value Permuted P
Contributing 
genes P value
Contributing 
genes
GO:0032365 intracellular lipid transport 9 1.71E-05 0.001 ABCA1, CPT1B – –
GO:0030301 cholesterol transport 8 1.79E-04 0.001 ABCA1, NPC1 0.048 ABCG1, CAV1, NPC1, NPC1L1
GO:0015918 sterol transport 8 1.79E-04 0.001 ABCA1, NPC1 0.048 ABCG1, CAV1, NPC1, NPC1L1
GO:0042632 cholesterol homeostasis 8 1.79E-04 0.001 ABCA1, NPC1 0.052 ABCG1, CAV1, NPC1, NPC1L1
GO:0055092 sterol homeostasis 8 1.79E-04 0.001 ABCA1, NPC1 0.052 ABCG1, CAV1, NPC1, NPC1L1
Table 1.  Lipid pathways down-regulated in experimental sleep restriction (SR) and epidemiological 
subjective sleep insufficiency (SSI). 4/5 of the top Gene Ontology (GO) Biological Processes that were found 
enriched among down-regulated transcripts in the experimental SR (permuted P < 0.001)5 were also identified 
among the genes with lower expression in DILGOM subjects with SSI. These pathways were involved 
in (chole)sterol transport and homeostasis, and contributed to the “Lipid cluster” (Cluster 5, P = 0.045, 
Supplementary Fig. S2). Down-regulation of the NPC1 gene was shared in both samples.
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as compared to the controls (Supplementary Table S4). The increased lipids comprised mostly polyunsaturated 
phosphatidylethanolamines (PE) and phosphatidylcholines (PC) (P < 0.05; Supplementary Table S4).
Network analysis on experimental SR. The findings from the SR study suggested that cholesterol trans-
port had declined and inflammation increased. An important transcriptional regulator of the RCT is the nuclear 
liver X receptor (LXR) signalling, which promotes RCT and decreases inflammation30–32. We thus hypothe-
sized that decrease in LXR activity could be mediating the effects of sleep restriction on the immune system and 
metabolism (Fig. 3, Table 2). Alternatively, the activity of lipid transfer proteins could be changed. To study these 
hypotheses and the associations between the observed changes, we selected relevant immunological, metabolic, 
and sleep variables measured in the experimental SR study (listed in Supplementary Table S5), including the 
parameters where changes had been detected also in the epidemiological cohorts, and performed a dependency 
network analysis (Supplementary Fig. S3).
Immunological parameters. Inflammation suppresses LXR activity via toll-like receptors (TLR)33–35. We have 
earlier shown that the gene coding for TLR4 was up-regulated in our 5 nights’ SR protocol5. Also proinflamma-
tory cytokines interleukin 1β (IL-1b) and tumour necrosis factor α (TNF-a) have been shown to suppress LXR 
activity36 (Fig. 3), and these cytokines have been consistently shown to increase in experimental sleep restric-
tion7,37. We observed higher expression of the gene encoding for TNF-a in free-living individuals with SSI in the 
DILGOM sample (pointwise P < 0.05), and genes encoding for both IL-1b and TNF-a in the Young Finns repli-
cation sample (P < 0.005 and P < 0.05, respectively) (Figs 2 and 3). In addition to the cytokines, up-regulation of 
inflammation-related genes encoding for TLR4 (Fig. 2), MyD88 (an essential signal transducer in the IL-1 and 
TLR pathways), inducible prostaglandin endoperoxide synthase (cyclooxygenase 2, PTGS2), and Fas cell surface 
death receptor (FAS) – observed in the experimental SR study – replicated in the YFS sample (Fig. 3). Increased 
inflammation could be further augmented through decreased LXR activity30.
Dependency network analysis. In order to distinguish direct and indirect interactions of these immune, meta-
bolic and sleep variables, we utilised undirected Gaussian graphical model where the variables are connected if 
and only if their partial correlation is significantly non-zero (using FDR multiple testing for the selection of edges) 
to visualise the dependencies as a network38.
The lipids that were increased after SR associated to several immunological parameters (Supplementary Fig. S3; 
P < 0.05 for all associations shown in the figure). The correlation analysis revealed significant positive associations 
with PE(38:3), PE(38:5e), PE(36:2e), ChoE(16:1) and B-cells. PE(38:3) was further negatively correlated with 
TNF-a, which was positively correlated with interleukins 18 and 1 and interferon-γ (IFNG). LXRA associated 
positively with B cells and TLR8, and negatively with ABCA1, NRIP1 and LXRB. TLR4 had a strong negative 
association with NPC1 and ABCA1 (Supplementary Fig. S3), as would be expected if LXR activity was decreased.
In the control subjects (Supplementary Fig. S4), the associations between the variables were fewer and weaker 
than in the experimental group. Particularly, scarce associations between the lipids and the immunological vari-
ables were observed. As the networks are baseline-corrected, they show the changes occurring between baseline 
and sleep restriction timepoint. As the control group was not subjected to any treatment (besides staying in the 
laboratory) between these timepoints, it was expected that no major changes would be detected.
Figure 1. Changes in lipoprotein particles in (A) experimental sleep restriction (SR) and (B) epidemiological 
subjective sleep insufficiency (SSI). Concentration differences of different sized very low density (VLDL), 
intermediate density (IDL), low density (LDL), and high density (HDL) lipoprotein particles. (A) Experimental 
SR compared to baseline (BL, normalised to 1) (*P < 0.05, paired t test; N = 14). (B) DILGOM subjects with SSI 
compared to subjects without SSI (noSSI, normalised to 1) (*pointwise P < 0.05, linear modelling adjusting for 
sex and age; N = 414).
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Lipid transfer protein and enzyme activities in SR. Lipid transfer proteins comprise the two key reg-
ulators of serum lipid balance between lipoproteins. However, we did not find significant changes in the activity 
of cholesterol ester transfer protein (CETP) or phospholipid transfer protein (PLTP) in the experimental SR 
study. Furthermore, no changes were observed in the activity of lecithin-cholesterol acyltransferase (LCAT), the 
enzyme converting HDL unesterified cholesterol to cholesteryl ester, or the atheroprotective enzyme paraoxonase 
1 (PON1) linked to antioxidative properties of HDL particles.
Discussion
The main finding of the present study was that restriction of sleep either experimentally or in natural living 
conditions modified lipoprotein metabolism and immune responses. The changes were detected at the level of 
transcriptome as well as in the circulating lipid profile. The transcriptional changes - the down-regulation of 
reverse cholesterol transport-related gene pathways - were similar in the relatively short term exposure of the 
experimental sleep restriction and in the epidemiological cohorts among subjects reporting insufficient sleep. 
Interestingly, the lipoprotein profile showed decreased LDL in experimental SR, resembling LDL changes in 
acute-phase response39, but in epidemiological SSI large HDL was decreased. Decrease in HDL has been regarded 
as one important risk factor for cardiovascular diseases40.
The classical view on the relationship between serum lipid levels and risk for cardiovascular events, formulated 
based on the findings of the Framingham study41 and since confirmed by many epidemiological studies, states 
that serum high LDL and low HDL cholesterol level is a risk combination for cardiovascular events42. These 
Figure 2. Replication in the Young Finns Study. Large (L) and extra-large (XL) HDL decreased with 
increasing level of subjective sleep insufficiency (SSI) (P < 0.005; N = 2077), whereas the expression of 
interleukin 1 β (IL1B) and toll-like receptor 4 (TLR4) genes was higher in subjects with SSI (P < 0.005 and 
P < 0.05, respectively; N = 1407). NoSSI = no or only mild SSI, mSSI = moderate SSI, hSSI = heavy SSI. 
HDL graphs represent mean ± s.e.m. concentrations in serum. Gene expression is shown relative to the 
mean expression in the noSSI group (relative mean ± s.e.m.). Effect of SSI on HDL concentrations and gene 
expression was modelled with linear regression adjusting for age and sex.
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Figure 3. Summary of the findings from the experimental and the epidemiological studies. (A) Proposed 
model to explain the findings. 1 Sleep loss activates inflammatory responses through toll-like receptors 
(TLR)5 2 suppressing liver X receptor (LXR) activity33–35. 3 Decreased LXR activity leads to decreased 
reverse cholesterol transport (RCT) and synthesis of fatty acids (FA) and triglycerides (TG), and increased 
immunological activation30–32. (Red arrows showing increase, green arrows decrease.) (B) The figure 
summarises our findings from transcriptomics and NMR metabolomics in experimental (E) sleep restriction 
(SR; N = 21), and in the DILGOM epidemiological cohort (D; N = 518) and Young Finns Study replication 
cohort (Y; N = 2221) subjects with subjective sleep insufficiency (SSI). Numbers 1 and 3 refer to the locations 
in the model proposed in Fig. 3A. (a) Up-regulation of TLR and other inflammatory genes/gene pathways in SR 
reported in5. Pathway analysis for up-regulated genes in subjects with SSI in DILGOM confirmed up-regulation 
of B-cell activation, lymphocyte activation, and immune system development (P < 0.05) also at epidemiological 
level. Individual genes showed only non-significant trends for higher expression in SSI. (b) TLR4 and several 
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findings have encouraged efforts to develop treatments with the aim of either to lower LDL levels (e.g. statins) or 
increase HDL levels (e.g. CETP inhibitors and niacin). Particularly the latter approach has been a disappointment: 
pharmacological increase of serum HDL levels has not affected the risk of cardiovascular diseases42, indicating 
that the mere serum HDL cholesterol concentration is not a sufficient metrics to explain its epidemiologically 
verified cardioprotective effect. HDL can protect against atherosclerosis by multiple mechanisms, including 
the ability to efflux cholesterol from endothelial macrophages (macrophage reverse cholesterol transport)43, or 
through anti-inflammatory44, antioxidative45 and antiapoptotic46 pathways. A newly discovered regulation by 
microRNAs adds to the complexity of the task to discover mechanisms that explain the relationship between HDL 
and cardiovascular disease (CVD) risks47. Moreover, modulations in HDL particle composition can transform it 
to dysfunctional and, through this modulation, increase the risk of CVD40.
Combining the knowledge of the epidemiologically verified increased risk for CVD associated with the low 
HDL/high LDL lipid profile and short/insufficient sleep, we expected to measure such lipid profiles in SR and in 
persons with SSI. This prediction did not prove quite correct. In SR we measured, using the NMR metabolom-
ics, decreased levels of LDL while we found no significant changes in HDL levels. In the SSI subjects we found 
decreased HDL levels but not significant differences in LDL levels. The one week experimental SR may have been 
too short to affect the number of HDL particles, while in the epidemiological samples, the number of large HDL 
particles was lower among those who reported insufficient sleep. Since the nature of conditions that induce insuf-
ficient sleep is often persistent48–51, we argue that the SSI subjects reporting insufficient sleep had been exposed to 
insufficient sleep for a longer period than those in the five day experimental sleep restriction study. We propose 
that the lipid profile is modulated in the course of exposure to insufficient sleep from low LDL levels at early phase 
of sleep insufficiency to low HDL levels upon longer exposure. However, in a cross-sectional study we cannot 
provide direct evidence on the duration of SSI for those who reported it. The low LDL concentration in the SR 
may have been induced by the inflammation, particularly by the activation of the acute phase response, induced 
by the sleep restriction5.
While some previous gene expression studies have indicated that cholesterol/lipid metabolism is regulated by 
sleep-wake cycle and sleep restriction could modify it8,52,53, detailed characterization of lipid profiles has remained 
scarce. It has been shown that serum triglyceride levels decreased following restriction of sleep to 4 hours on 5 
inflammation-related genes had higher expression among subjects with SSI in the replication sample Young 
Finns Study. (c) Increase in proinflammatory cytokines IL-1b and TNF-a assessed by in vitro stimulation of 
white blood cells and reported in7. (d) Higher expression of genes encoding for proinflammatory cytokines at 
epidemiological level in subjects with SSI. (e) Down-regulation of genes/gene pathways of reverse cholesterol 
transport assessed with transcriptomics and reported in the present publication. Concentrations of large HDL 
in serum measured using NMR metabolomics. (f) Acetyl-CoA carboxylase (ACC), the rate-limiting enzyme 
of FA synthesis, was down-regulated in SR and DILGOM SSI. No major differences were observed in the 
expression of other FA and TG synthesis genes in SR or SSI. (g) FA and TG measured with NMR metabolomics 
in experimental SR and DILGOM. Paired t tests used for comparing SR to BL, and linear regression used 
for modelling the effect of SSI on gene expression or lipid concentration, adjusting for age and sex. See 
abbreviations in Table 2.
Abbreviation Definition
TLR4, TLR2 toll-like receptors 4 and 2
NF-kB nuclear factor kappa B
MyD88 myeloid differentiation primary response 88
PTGS2 prostaglandin synthase 2 = inducible cyclooxygenase
iNOS inducible nitric oxide synthase
IL6 interleukin 6
FAS Fas cell surface death receptor
IL-1b interleukin 1 β 
TNF-a tumour necrosis factor α 
ABCA1, ABCG1 ATP-binding cassette (ABC) transporters A1 and G1
NPC1 Niemann-Pick disease 1
ARL7 ADP-ribosylation factor-like 7
PLTP phospholipid transfer protein
L HDL large high density lipoprotein particles
SREBF1 sterol regulatory element binding transcription factor 1
FASN fatty acid synthase
ACC acetyl-CoA carboxylase
FA fatty acids
TG triglycerides
Table 2.  Variables in Fig. 3B.
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consecutive nights12, and also that myeloperoxidase-modified LDL particles increased under similar conditions13. 
In a recent study, no changes in blood total cholesterol, LDL, HDL, or triglycerides were found after sleep restric-
tion to 4 hours on 5 nights14. Two recent studies have measured lipid profiles in human blood samples using mass 
spectrometry analysis after polar and non-polar extraction of the samples after a short term (24 h) total sleep 
restriction22 and a partial sleep restriction for five days23. In both studies, the majority of the altered, identified 
species, consisted of lipid species (including phospholipids, sphingolipids, acylcarnitides and phosphatidylcho-
lines). In the acute SR study22, only increases in lipid levels were observed after the deprivation period, while 
in the partial SR study23 also declines were recorded. In the present SR study, all significant changes from BL to 
SR, measured using the mass spectrometry technique, were increases, mainly in phosphatidyl ethanolamides, 
phophatidyl cholines, triglycerides and cholesterol esters. In spite of some discrepancies in the results, possi-
bly explained by different extraction and other methods and/or differences in the experimental arrangements, 
these three independent studies point out that restriction of sleep, either acutely or partially for a longer period, 
significantly affects serum lipid levels, as measured using mass spectrometry. In the present study, also NMR 
spectroscopy measurement was able to track changes in lipid profiles under conditions of restricted sleep, further 
confirming that this condition modifies lipid metabolism.
The results from the gene expression pathways were more consistent than those of the lipid profiles. The cho-
lesterol pathways that were down-regulated in SR and SSI included members of the ATP-binding cassette families 
A and G (ABCA1 and ABCG1). ABCA1 and ABCG1 facilitate the efflux of free cholesterol and phospholipids 
from macrophage-foam cells to HDL particles. Of all cholesterol carried by HDL, the proportion originating 
from peripheral macrophages is low compared to liver (75%) and intestine (20%) produced HDL. However, this 
route of removal of cholesterol (macrophage RCT) has been regarded as an important (but not only) component 
in retaining cholesterol balance in arterial endothelium43. Since ABCA1 and ABCG1 work in tandem to facili-
tate cholesterol removal from the macrophages54, the reduction in their expression would implicate a reduced 
potential of these monocyte-derived macrophages to egress cholesterol to HDL acceptors55. ABCA1 deficiency 
in Tangier disease leads to very low or absent HDL levels and larger VLDL particles56. Since the relationship 
between cholesterol transporter expression in white blood cells and serum HDL concentration is far from simple, 
it is difficult to evaluate how the observed expression changes were reflected to the flow of cholesterol from mac-
rophages to liver and finally feces (RCT), particularly as the activities of the enzymes/transporters modulating 
HDL pool (CETP, PLTP, LCAT, PON1) measured in the SR study were not affected by. However, it can be noted 
that the observed expression changes in the cholesterol transport-related genes are compatible with those in 
down-regulation of LXR activity39,57 (Fig. 3).
Caveolin-1 (CAV1) is found in caveolae, cholesterol-rich membrane lipid formations that are involved in 
cholesterol traffic and homeostasis58 and regulation of inflammation59 among other functions. CAV1 has been 
proposed to participate in the regulation of cholesterol efflux to HDL60,61, possibly in interaction with ABCG161. 
Some other studies have not found an effect62,63, and the overall effect of CAV1 on cholesterol efflux is complex61. 
The observed decrease in CAV1 expression may add to the view that reverse cholesterol transport from mac-
rophages is compromised by insufficient sleep.
Previous studies indicate that the immune system is activated during experimental sleep restriction, and in 
persons who in epidemiological studies report short sleep duration (reviewed in64,65). We have earlier shown that 
cytokine (interleukins IL-1b, IL-6 and IL-17) release as response to in vitro immunological challenge is increased 
after sleep restriction, as well as serum acute phase protein CRP7. At gene expression level, the activation included 
increases in expression of toll-like receptors, NF-kB signalling pathway and interleukin-8 production pathways5.
Many acute conditions, including surgical trauma, myocardial infarction and inflammation, induce the sys-
temic acute phase reaction (APR), with acute phase protein production in the liver as an integral part of the host 
defence response. In addition to changes in protein synthesis, also lipid metabolism undergoes significant mod-
ifications in APR66,67. Metabolic modifications aim at optimization of the defence, and would return to baseline 
level after the need for defence has disappeared68. However, if the inflammation-sustaining condition continues, 
as presumably in the epidemiological SSI groups of the present study, the metabolic modifications may develop 
further and become chronic39,68. Moreover, the modifications differ according to the nature of the event that 
aroused the reaction, e.g. surgical trauma and infection66,68. Decreases in HDL and LDL cholesterol, as well as 
RCT, belong to the metabolic adaptations found in APR during inflammatory attack67. While cytokines (includ-
ing IL-1b, IL-6 and TNF-a) are central regulators of the APR, recent research suggests that an important part of 
the metabolic regulation in APR is channelled via nuclear receptors, including LXR, PPAR and LHR-139. Thus 
both the down-regulation of RCT pathway and up-regulation of the inflammatory pathways could result from a 
decrease of LXR activity (Fig. 3).
Methodological issues. To evaluate sleep in the epidemiological samples, we used subjective evaluation 
of sleep insufficiency, instead of sleep duration. While sleep duration as a measure of sleep has many advan-
tages, in evaluation of sleep insufficiency it has one considerable disadvantage: it cannot differentiate sleep 
insufficiency-inducing short sleep from natural short sleep69.
In epidemiological studies sleep duration and self-reported sleep insufficiency have shown independent effects 
on cardiovascular outcomes (including hypertension, cholesterol level and cardiac events)70 and performance71. 
Thus, although the correlation of short sleep duration and subjective sleep insufficiency is usually high (in the 
present study, P = 2.5E-10 and β = − 0.5 h in DILGOM, and P = 4.9E-93 and β = − 0.5 h in YFS, Supplementary 
Fig. S5), these variables may represent partly overlapping, but separate physiological entities69,70. In epidemiolog-
ical studies, a question addressing sleep need and/or subjective feeling of sleep insufficiency may help to separate 
natural short sleepers from those that don’t get enough sleep.
While the participants of the experimental study were carefully screened not to have any (sleep) disorders, the 
participants in the epidemiological studies reported different medical conditions, including sleep apnoea, which 
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is known to be associated to both insufficient sleep and cardiovascular diseases. The evaluation of the potential 
effects of OSA on our results revealed that although the subjects reporting symptoms of OSA reported also more 
sleep insufficiency, OSA did not explain the difference in HDL, as SSI was independently associated to lower level 
of large HDL.
The main regulation of metabolism takes place in other tissues (e.g. liver, pancreas) than blood cells, which 
were used in the gene expression analyses. Thus it is unclear to which extent the results reflect changes in the 
actual metabolic processes. An additional source of variation lies in the differences in age and gender between 
the populations studied. The effects of these factors have been addressed by including them in the linear models 
used for statistical analyses.
Sleep loss is often accompanied with circadian misalignment, also known to cause changes in the regulation of 
the immune system and metabolism and associate to cardiovascular diseases72,73. In our experimental SR study, 
the modest delay (16 min) in circadian rhythm, measured in the morning salivary cortisol peak, is unlikely to 
significantly modulate the results, but the effect cannot be entirely ruled out.
In real life, people frequently experience consecutive cycles of sleep restriction and recovery sleep (e.g., shift 
workers, people working extended days). Often recovery sleep between two periods of sleep restriction remains 
incomplete and induces a carry-over effect74. In the SR experiment, participants were subjected to only one cycle. 
From this perspective, the results of the SR study may underestimate what actually happens to the cholesterol 
metabolism of sleep-restricted individuals in real life.
We propose that sleep restriction arouses a host defence response that shares features with APR aroused by 
trauma and infection. These responses modulate lipid metabolism, possibly through LXRs, and in the long run 
may contribute to the increased risk of cardiovascular diseases.
Conclusion
Sleep restriction-induced decrease in expression of genes in pathways related to reverse cholesterol transport 
from macrophages, in combination with inflammatory activation, may at least partly explain the increased risk 
for cardiovascular diseases established in epidemiological studies for persons with short/insufficient sleep.
Methods
Samples. Experimental sleep restriction. An experimental schedule simulating a working week with 
restricted sleep was executed at the Brain and Work Research Centre of the Finnish Institute of Occupational 
Health (FIOH). We have earlier reported changes observed in glucose metabolism75, cytokines, white blood 
cell subpopulations, and C-reactive protein7, leukocyte gene expression5, as well as cognitive performance76 
from this SR experiment. Study participants were men (N = 21; age 19–29 years; mean ± s.d. 23.2 ± 2.2 years; 
Supplementary Table S1) with regular sleep wake cycle that was checked by wrist-worn actigraphy and sleep 
diaries during 1–2 weeks prior to the study. In the sleep laboratory, the participants were randomly allocated to 
the experimental group (“cases”; N = 14) or the control group (“controls”, N = 8) (Supplementary Fig. S1). Cases 
spent the first two nights 8 h/night in bed (baseline, BL; from 23:00 h to 07:00 h), followed by five nights of 4 h/
night in bed (sleep restriction, SR; from 03:00 h to 07:00 h). Controls spent 8 h in bed every night. One control 
subject was excluded after the EEG analysis as he had been sleeping less than 6 h/night during the experiment. 
Total sleep duration in the cases (N = 14) decreased from 7 h 22 min ± 20 min in BL to 3 h 54 min ± 5 min in SR, 
while it remained relatively constant, 7 h 19 min ± 16 min to 7 h 26 min ± 17 min at the same timepoints, in the 
controls (N = 7).
During waking, main activities of the participants included training and testing of memory and motor tasks 
simulating office work tasks. These tests were conducted during the day at 10:00–12:30 and 14:30–15:40, and 
during the sleep restriction at 00:30–01:40. In the test room the illumination ranged from 150 to 400 lux and in 
the living room from 350 to 600 lux. Physical exercise or leaving the sleep laboratory was not allowed during the 
experiment. Polygraphy was measured continuously and EEG scored according to the Rechtschaffen-Kales man-
ual75,77. EEG data from the previous night before morning blood sample-taking for timepoints BL and SR were 
included in the dependency network analysis.
Prestudy mean (± s.d.) body mass index (BMI) was 23.2 (± 2.4) for controls and 23.5 (± 2.6) for cases. 
Standardised meals based on the Finnish nutrition recommendations for 18–30 years old normal-weighted men 
with low activity78 were eaten at fixed times throughout the experiment: breakfast at 08:00 h (600 kcal), lunch at 
12:30 h (800 kcal), dinner at 18:30 h (700 kcal); snacks at 15:30 h (300 kcal) and 21:30 h (200 kcal). In addition, 
cases ate a piece of fruit (apple or orange) at 00:30 h (50 kcal) which did not exceed the estimated increase of 
energy expenditure during the SR79. No caffeine, alcohol, or tobacco was allowed during the experiment. Blood 
samples were collected at BL and SR timepoints at 7.30 h after fasting overnight.
Saliva cortisol was assessed 10 times per day during the experiment, and only a modest, 16 min on average, 
delay in the circadian phase measured by the morning peak of cortisol (from mean ± s.d. 07:39 ± 0:14 in BL to 
07:55 ± 0:11 in SR) was observed in the sleep-deprived cases75. No changes in the overall cortisol concentration 
in SR compared to BL was observed7.
The DILGOM cohort. The Dietary Lifestyle and Genetic determinants of Obesity and Metabolic Syndrome 
(DILGOM) study was originally performed as an extension of the FINRISK 2007 study (N = 7993; age 25–74 
years; from five geographical areas in Finland). The national, cross-sectional FINRISK surveys have been carried 
out every 5 years since 1972 to assess the risk factors of chronic diseases (e.g. CVD, diabetes, obesity, cancer) and 
health behaviour in the working age population in Finland. The aim of the DILGOM study (N = 5024) was to 
characterise risk factors for metabolic and cardiovascular diseases in the Finnish population both at the epide-
miological and at the genetic level25. In addition to questionnaire data on health and lifestyle, a blood sample was 
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drawn after at least 10 h of overnight fasting for genetic and biomedical analyses. Time of sampling varied from 
7:11 a.m. to 11:31 a.m., with mean 8:56 a.m. (± s.d. 58 min).
NMR metabolomics and genome-wide gene expression were measured for a subsample from Helsinki metro-
politan area (N = 518, age 25–74 years, 54% females, Supplementary Table S1, Supplementary Fig. S1)80. For the 
present study, these measures were correlated with a question probing subjective feeling of insufficient sleep. The 
question was ”Do you, in your opinion, sleep enough?”, and it had four answer options: 1) “Yes, almost always” 
(N = 168), 2) “Yes, often” (N = 218), 3) “Seldom or almost never” (N = 86), and 4) “I cannot say” (N = 46). 
Answer 4 was excluded, and answers 1–3 (N = 472) were dichotomised combining 1 and 2 to a phenotype of 
‘subjective sufficient sleep’ (noSSI, N = 386) and comparing this to 3, ‘subjective sleep insufficiency’ (SSI, N = 86). 
Habitual sleep duration was assessed with the question “How many hours, on average, do you sleep per night?” 
with a free entry answer in hours.
The Young Finns Study (YFS) cohort. The Cardiovascular Risk in Young Finns Study (“Young Finns Study”, 
YFS) is a Finnish prospective multi-centre cohort26. It aims to study cardiovascular risk factors in children and 
adolescents (aged 3, 6, 9, 12, 15 and 18 at baseline). The study participants were randomly selected in 5 centres in 
Finland. The baseline study was conducted in 1980 (N = 3596). Sleep parameters were assessed with a question-
naire in 2007 when the study subjects were 30 to 45 years of age (Supplementary Table S1, Supplementary Fig. S1). 
Blood samples were collected after overnight fasting (97.4% of the subjects reported to have fasted overnight 
before the sample taking as requested and 1.3% not to have, while no information on fasting was obtained for 
1.4%). The mean time of sampling was 9:46 a.m. (± s.d. 1:38).
In this cohort, subjective sleep insufficiency was assessed using two questions. Subjects reported their habitual 
sleep duration on a 10-level scale (≤ 5 h, 6 h, 6.5 h, 7 h, 7.5 h, 8 h, 8.5 h, 9 h, 9.5 h, or ≥ 10 h). They also evaluated 
their subjective sleep need (“How many hours of sleep do you need per day to feel well rested?”) on the same scale. 
A measure of subjective sleep insufficiency for each subject was formed by subtracting the sleep duration from the 
sleep need. Subjects (N = 2221 with SSI data) were grouped into three groups based on their level of SSI: no (or 
only mild) SSI (sleep need – sleep length = − 1… 0… 1 h; N = 1825), moderate SSI (1.5–2 h; N = 304), and heavy 
SSI (> 2 h; N = 55). Subjects sleeping more than 1 h over their subjective sleep need (N = 37) were not included in 
the analyses. Correlation of sleep insufficiency with sleep duration is shown in Supplementary Fig. S5).
Possible self-reported OSA was estimated using questions addressing the frequency and quality of snoring, as 
described earlier81. The questions used were “How often do you snore?”, “What does your snoring sound like?”, 
and “Have you noticed (or have others noticed) respiratory pauses when you sleep?”. Self-reported probable 
OSA was diagnosed if snoring was frequent (at least 3–5 nights per week) and either of the following was true: a) 
snoring was loud and irregular, with occasional respiratory pauses and/or stertorous breathing, or b) respiratory 
pauses at least 1–2 nights per week. The prevalence of probable self-reported OSA in the YFS sample using these 
criteria was 5%.
Measures. Expression microarrays. DILGOM cohort. Genome-wide gene expression analysis was 
performed for 518 individuals (Supplementary Fig. S1). Gene expression was detected and data processed as 
described in80. Briefly, peripheral blood total RNA was extracted with PAXgene Blood RNA Kit (Qiagen GmbH, 
Hilden, Germany). RNA quantity and quality was evaluated with 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA). 200 ng of total RNA from each sample was used for production of biotinylated cRNA with 
Ambion Illumina TotalPrep RNA Amplification Kit (Applied Biosystems, Foster City, CA, USA). 750 ng of bioti-
nylated cRNA was hybridised onto Illumina HumanHT-12 Expression BeadChips (Illumina Inc., San Diego, CA, 
USA). Biotinylated cRNA preparation and hybridization onto BeadChip were done in duplicates for each sample.
Statistical analysis. All arrays were quantile normalised at the strip-level. Technical replicates were combined 
via a bead-count weighted average, and replicates with Pearson’s correlation coefficient < 0.94 or Spearman’s rank 
correlation coefficient < 0.60 were removed from further analysis. 472 subjects with gene expression and sleep 
sufficiency data were included in the final analysis. 35,420 probes were analysed.
Subjects were grouped into two groups (SSI, noSSI) based on their report of subjective sleep insufficiency. 
Linear regression was used to correlate RNA expression with SSI, adjusting for age and gender (R version 2.14).
Young Finns Study cohort. Genome-wide gene expression was detected using Illumina microarrays as described 
in82. Briefly, 2.5 ml of whole blood was collected to a PAXgene Blood RNA Tubes (PreAnalytix, Hombrechtikon, 
Switzerland) after fasting overnight. RNA was isolated with PAXgene Blood RNA Kit (Qiagen) with DNase Set 
according to manufactures instructions using the QiaCube.
The concentrations and purity of the RNA samples were evaluated spectrophotometrically with NanoDrop 
(BioPhotomer, Eppendorf, Wesseling-Berzdorf, Germany). Samples were considered pure, if the 260/280 ratio 
was 1.8–2.2. The RNA isolating process was validated by analysing the integrity of RNA with the RNA 6000 Nano 
Chip Kit (Agilent).
The expression levels were analysed with an Illumina HumanHT-12 version 4 Expression BeadChip (Illumina 
Inc.) containing 47,231 expression and 770 control probes. In brief, 200 ng of RNA was reverse-transcribed into 
cDNA and biotin-UTP-labelled using the Illumina TotalPrep RNA Amplification Kit (Ambion); 1500 ng of cDNA 
was then hybridised to the Illumina HumanHT-12 v4 Expression BeadChip. The BeadChips were scanned with 
the Illumina iScan system.
Statistical analysis. Raw Illumina probe data was exported from GenomeStudio and analysed in R (http://
www.r-project.org/) using the Bioconductor (http://www.bioconductor.org/) packages. The expression data was 
processed using nonparametric background correction, followed by quantile normalization with control and 
expression probes, using the neqc function in the limma package and log2 transformation. The expression anal-
ysis was successful for 1650 subjects.
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Subjects were grouped into three groups based on their level of subjective sleep insufficiency (noSSI, moderate 
SSI, heavy SSI; N = 1407). Linear regression was used to correlate RNA expression with SSI, adjusting for age and 
gender (R version 2.14).
Pathway analysis. The genes with differing expression levels in the SSI group compared to subjects satisfied 
with their sleep amount (P < 0.05) in the DILGOM cohort were further analysed with Database for Annotation, 
Visualization and Integrated Discovery (DAVID) pathway analysis (DAVID Bioinformatics Resources 6.7, 
NIAID/NIH, http://david.abcc.ncifcrf.gov/home.jsp). Illumina probe IDs were converted to DAVID IDs using 
Gene ID Conversion Tool, removing all redundancies in the original IDs. DAVID Functional Annotation Tool 
was used for identifying enriched biological processes among the genes with lower or higher expression in the SSI 
group (analysed separately; N genes 725 and 734, respectively) compared to the whole human genome28. Gene 
Ontology (GO) Biological Process annotations were used and pathways with less than 3 genes from our gene list 
were excluded. Other than this, default parameters were used in the analysis. Considering the hierarchical nature 
of GO annotations, the GO pathways were grouped using DAVID Functional Annotation Clustering. Medium 
classification stringency and other default parameters were used.
NMR spectroscopy. The NMR-based analyses provide absolute quantification of multiple serum metabolites, 
including lipoprotein subclass distribution, fatty acids, and various small molecules including amino acids and 
glycolysis precursors (Supplementary Table S3). The lipoprotein subclasses were classified as follows: chylomi-
crons and extremely large VLDL particles (average particle diameter at least 75 nm); five different VLDL sub-
classes: very large VLDL (average particle diameter of 64.0 nm), large VLDL (53.5 nm), medium VLDL (44.5 nm), 
small VLDL (36.8 nm), and very small VLDL (31.3 nm); intermediate-density lipoprotein (IDL) (28.6 nm); three 
LDL subclasses: large LDL (25.5 nm), medium LDL (23.0 nm), and small LDL (18.7 nm); and four HDL sub-
classes: very large HDL (14.3 nm), large HDL (12.1 nm), medium HDL (10.9 nm), and small HDL (8.7 nm). The 
NMR-based metabolite profiling has previously been used in various epidemiological and genetic studies83–85 and 
details of the method have been described25,29,86.
Statistical analysis. The concentrations of 135 serum metabolites were assessed with NMR spectroscopy from 
serum samples of the experimental SR study and the epidemiological cohorts. In the SR study, SR timepoint was 
compared to BL with paired t tests. Hierarchical clustering analysis using principal components revealed that the 
135 metabolites cluster into 21 clusters that explain 95% of the variance. P values from the t tests were corrected 
with the amount of clusters (N = 21).
In the epidemiological samples DILGOM and YFS, linear regression was used to correlate NMR metabolites 
with SSI, adjusting for age and gender (R version 3.0), similarly as was done in the gene expression analysis. In the 
YFS sample, the analyses were run also with self-reported probable OSA added in the model.
Mass spectrometry. Lipidomic analyses were performed on serum samples from the experimental SR study 
at VTT Technical Research Centre of Finland. Ultra Performance Liquid Chromatography (UPLC) coupled to 
electrospray ionization quadrupole time-of-flight mass spectrometry (QTOFMS) was used with the established 
protocol87. Data was processed using the MZmine 2 software88. The data was normalised using internal standards 
representative of each class of lipid present in the samples. A total of 530 lipids were detected and 330 identified.
Statistical analysis. BL-normalised values of the lipids in the SR timepoint were compared between cases and 
controls using t tests.
Lipid transfer protein and enzyme activity assays. CETP activity was analysed as the transfer/exchange of radi-
olabelled [14C]cholesteryl oleate between exogenously added human LDL and HDL2, as described in89. PLTP 
activity was assessed with phosphatidylcholine liposomes following an earlier reported protocol90. Liquid scin-
tillation counting was used to detect radioactivity in HDL as a measure of transfer activity. LCAT activity was 
assessed by measuring cholesterol esterification activity using exogenous [3H]cholesterol-labelled HDL proteo-
liposome discs as the substrate91. Serum PON1 activity was measured using spectroscopy method and Paraoxon 
(diethyl-p-nitrophenyl phosphate; Sigma) as the substrate92.
Statistical analysis. The activities in the SR timepoint were compared to their BL using first 2-way repeated 
measures ANOVA with group (case vs control) and timepoint (BL vs SR) (R version 3.0), and then with paired t 
tests between the two timepoints.
Dependency network analysis. Partial correlation network analysis using the undirected Gaussian graphical 
model (Genenet package38) was performed on baseline-normalised data for cases and controls separately, by 
using the log2 of the ratio between the SR and BL timepoints. Unlike the pairwise measures of associations such 
as Pearson correlation coefficient, partial correlation provides a stronger criterion for dependency by adjusting 
for confounding effects, and thus removing spurious associations to a large extent. This is particularly favourable 
for an integration of multiple layers of information as in our study, because it inherently filters out false positives 
by discovering only direct interactions with high confidence.
52 variables from the SR study were selected for the network analysis and are listed in Supplementary Table S5. 
The eleven lipid molecular species included in the network analysis were those lipids that showed differences 
(t test, P < 0.05) between cases and controls at SR timepoint for BL-normalised data. The sleep variable data used 
were those from the previous night before the blood sampling (second night of BL and fifth night of SR).
In these networks non-missing edges denote non-zero partial correlations (P < 0.05) between pairs of var-
iables and thus imply direct interactions. The edge width is proportional to strength of dependency. The node 
colour corresponds to the significance and direction of regulation comparing cases versus controls. The yED 
graphical editor93 was used for network´s visualization.
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Study approval. This study was conducted according to the Declaration of Helsinki principles, and written 
informed consent was obtained from all participants. The experimental sleep restriction study protocol and the 
FINRISK 2007 study including the DILGOM subsample were approved by the coordinating ethics committee 
of the Hospital District of Helsinki. The Cardiovascular Risk in Young Finns Study was approved by the ethics 
committees of University Hospitals of Turku, Helsinki, Tampere, Kuopio, and Oulu.
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